Adaptive Phage Therapeutics

Gold Sponsor

APT is a clinical-stage biotech advancing therapies for AMR infections. The AMR crisis is caused by ongoing evolution of bacteria, driving traditional antibiotics to fail commercially and therapeutically. APT’s phage bank is designed to overcome AMR with an ever-expanding library of phages that collectively provide broad spectrum coverage. APT precision matches bacteria to its phages through a susceptibility assay that APT has teamed with Mayo Clinic to commercialize on a global scale. APT’s technology was  developed at the NIH and further advanced within a biodefense program of U.S. military. APT acquired world-wide rights in 2017. Visit http://www.aphage.com.



GET INVOLVED AT THE

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


Semen Sen

semen.sen@terrapinn.com
+1 646.619.1793

 

 

To Speak

 


Emma Goaley

emma.goaley@terrapinn.com
+1 646.400.2576

 

 

Press & Media Partnerships

 


Ipek Coskun

ipek.coskun@terrapinn.com
+1 407.421.5818